electroCoreECOR
ECOR
About: electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Employees: 62
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
8% more capital invested
Capital invested by funds: $6.61M [Q2] → $7.15M (+$545K) [Q3]
7.0% more ownership
Funds ownership: 16.49% [Q2] → 23.49% (+7.0%) [Q3]
0% more funds holding
Funds holding: 22 [Q2] → 22 (+0) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$25
57%
upside
Avg. target
$25
57%
upside
High target
$25
57%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 58 / 186 met price target | 57%upside $25 | Buy Maintained | 18 Dec 2024 |
Financial journalist opinion
Positive
Seeking Alpha
1 week ago
electroCore: An Opportunity In Medical And Wellness Device Innovation
electroCore, Inc. (ECOR) shows promising growth with a 45% YoY revenue increase and a 38% loss reduction, despite missing revenue expectations. The company's gammaCore device is FDA-cleared for headaches, and expanding product lines indicate strong potential and barriers to entry. Management is focused on profitability, rather than international expansion, with high gross margins and decreasing OPEX as a percentage of revenue.
Positive
Seeking Alpha
3 weeks ago
electroCore Has Only Just Begun To Scratch The Surface Of Its Huge TAM
electroCore's gammaCore, an FDA-approved nVNS device, generates recurring revenue and has significant expansion potential within the VA system and other healthcare channels. The company is diversifying with the rugged TAC-STIM for military use and the consumer-focused Truvaga Plus, targeting wellness markets. The recent acquisition of NeuroMetrix's Quell system for fibromyalgia offers revenue and cost synergies, leveraging electroCore's established sales channels.
Neutral
GlobeNewsWire
1 month ago
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector
Neutral
GlobeNewsWire
2 months ago
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York City on November 21, 2024.
Neutral
Seeking Alpha
2 months ago
electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the electroCore Third Quarter 2024 Earnings Conference Call.
Negative
Zacks Investment Research
2 months ago
ElectroCore, Inc. (ECOR) Reports Q3 Loss, Tops Revenue Estimates
ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.68 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
electroCore Announces Third Quarter 2024 Financial Results
Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales
Neutral
GlobeNewsWire
2 months ago
ElectroCore's Truvaga™ Plus Wins Men's Health Magazine Tech Award
ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been awarded the prestigious Men's Health Magazine Tech Award for a pioneering wellness device recognized for innovation and excellence. The award celebrates groundbreaking advancements in health and technology and highlights products that significantly impact men's health and wellness. A link to the article can be found here: Men'sHealth Tech Awards 2025.
Positive
Zacks Investment Research
2 months ago
Strength Seen in electroCore (ECOR): Can Its 6.0% Jump Turn into More Strength?
electroCore (ECOR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
GlobeNewsWire
2 months ago
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company's VP, Corporate Controller. The Compensation Committee of electroCore's Board of Directors granted 5,000 restricted stock units (“RSUs”) to Mr. Freeburg in connection with the commencement of his employment. The RSUs were granted as an inducement material to Mr. Freeburg's commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Mr. Freeburg's continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company's common stock.
Charts implemented using Lightweight Charts™